Neurostellar
Envisions a reality where people could tackle these shackles with technology and interact with their surroundings using just thoughts or have a telepathic voice call with your colleagues on the other side of the globe or play video games just with your mind.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $150k | Angel | |
| Total Funding | 000k | ||
| USD | 2022 | 2023 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
NeuroStellar is a medical technology company focused on developing a non-invasive brain-computer interface (BCI) for monitoring brain activity. The company was co-founded in 2022 by CEO Olimpia Onelli and CTO Elliot Doazan. Onelli brings a background in neuroscience and commercialization from her time at Imperial College London, while Doazan has expertise in micro-fabrication and neurotechnology, also from Imperial College. The founding team's journey began during their respective PhD and MRes programs at Imperial College, where they identified the limitations of current brain monitoring technologies like EEG and fMRI, which often suffer from low-resolution data or require invasive procedures.
The company's core product is a wearable headset that utilizes optically pumped magnetometers (OPMs) to conduct magnetoencephalography (MEG) scans. This technology aims to provide high-resolution data on brain activity, comparable to traditional MEG systems, but in a more accessible and non-invasive format. The device is designed to measure the weak magnetic fields generated by neural currents, offering a detailed picture of brain function. NeuroStellar's target market includes researchers and clinicians in the neurology and mental health sectors. The primary business model appears to be the sale of this advanced BCI hardware to research institutions and healthcare facilities for applications such as diagnosing neurological disorders like epilepsy and depression, as well as for neuroscience research.
The key advantage of NeuroStellar's system is its potential to deliver the high-fidelity data of conventional MEG scanners, which are large, expensive, and require magnetically shielded rooms, in a portable, cost-effective, and user-friendly device. This could significantly broaden the accessibility of detailed brain activity mapping. The company has participated in several accelerator programs, including Conception X, and has received support from institutions like Imperial College London, the National Institute for Health and Care Research (NIHR), and the Royal Academy of Engineering.
Keywords: neurotechnology, brain-computer interface, BCI, magnetoencephalography, MEG, medical device, neuroscience, OPM, brain monitoring, neurology